Revenue
2019
2020
2021
2022
2023
2024
2025
AbCellera Biologics Inc. (ABCL)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $75.1M | $28.8M | $38.0M | $485.4M | $375.2M | $233.2M | $11.6M |
| Research & development | $186.8M | $167.3M | $175.7M | $107.9M | $62.1M | $29.4M | $10.1M |
| Operating expenses | $292.2M | $343.6M | $275.2M | $268.9M | $170.8M | $77.1M | $15.7M |
| Operating income | −$217.1M | −$314.8M | −$237.2M | $216.5M | $204.4M | $156.0M | −$4.1M |
| EBITDAderived | −$195.0M | −$287.9M | −$212.8M | $244.4M | $218.9M | $160.9M | −$2.5M |
| Net income | −$146.4M | −$162.9M | −$146.4M | $158.5M | $153.5M | $118.9M | −$2.2M |
| Basic EPSper diluted share | -$0.49 | -$0.55 | -$0.51 | $0.56 | $0.56 | $0.53 | -$0.01 |
| Diluted EPSper diluted share | -$0.49 | -$0.55 | -$0.51 | $0.50 | $0.48 | $0.45 | -$0.01 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 14, 2026Form 4 | Montalbano John S.Director | BuyCommon Shares | 20.0K | $4.77 | $95.4K | 241.0K |
| Feb 27, 2026Form 4 | Thermopylae Holdings Ltd.TenPercentOwner | BuyCommon Shares | 38.0K | $3.44 | $130.7K | 56.13M |
| Feb 27, 2026Form 4 | Booth AndrewChief Financial Officer | BuyCommon Shares | 42.6K | $3.42 | $145.7K | 195.6K |
| Feb 26, 2026Form 4 | Thermopylae Holdings Ltd.TenPercentOwner | BuyCommon Shares | 177.5K | $3.27 | $580.3K | 56.10M |
| Nov 26, 2025Form 4 | Montalbano John S.Director | BuyCommon Shares | 50.0K | $3.57 | $178.5K | 221.0K |